Tuesday, November 12, 2013

Watch:AASLD Internet Symposium And Review November HCV Newsletters

AASLD Internet Symposium And November HCV Newsletters

Hello, and welcome to the second week of November.

Today, in my part of the world we had our first dusting of snow, a reminder that winter is not far off.

I hope everyone is in the mood for reading, if not sit back and watch an educational activity presented by one of my favorite websites.

Just launched online by ViralEd is an Internet symposium discussing key studies on current and future drugs to treat chronic hepatitis C, presented at the 64th AASLD. 

The 1.5 hour symposium will feature 4 well-known and recognized thought leaders in the HCV field; Fred Poordad, MD ( looking hot in his bow tie), K. Rajender Reddy, MD., Mark Sulkowski, MD., and Nezam H. Afdhal, MD.

Navigating The On Demand Presentation

The good news? No navigating. Just click here, enter your name and email address and click "Go To Program"

AASLD 2013 Internet Symposium


Hot Topics

A collection of  "Hot Topics" with links to interim data on experimental HCV drugs presented at this months liver meeting are included further down this post, following the summary of November Newsletters.

November HCV Newsletters

This months index of newsletters is chock full of helpful hepatitis C information. 

American Liver Foundation
 Liver Lowdown is the monthly general interest e-newsletter of the American Liver Foundation.

In accordance with the Foundation’s mission, the e-newsletter is disseminated to provide information about the prevention, treatment and cure of liver disease, as well as the organization’s research and advocacy endeavors.

Content includes updates about the Foundation’s educational and signature programs; an in-depth focus on specific types of liver disease, and profiles of liver patients’ and caregivers’ personal experiences

November Newsletter

6 Things You Should Know About Liver Cancer
What’s the difference between primary liver cancer and metastatic liver cancer? If you have liver cancer, are there always clear-cut symptoms? And what should you do if you think you’re at risk? Find the answers to these and other important questions.
 ALF Website
The Hepatitis C: Diagnosis, Treatment, Support website
1-800-GOLIVER (1-800-465-4837)

In addition, questions sent on e-mail to info@liverfoundation.org will be promptly answered.

Stay Connected

Join Our Mail List
 Check Us Out On Twitter and Facebook
  Twitter  Facebook

NYC Viral Hepatitis Monthly E-Newsletter

November Newsletter


BOOM! Health  
New social marketing ad campaign on 60 MTA buses and multiple subway stops encourages Bronx residents to know their HIV and hep C status by getting tested and engaging in treatment.

NASTAD. Provides recommendations for policymakers to better equip state and local health departments to provide the basic, core public health services to combat viral hepatitis; increase surveillance, testing and education efforts nationwide; and effectively reach the goals set by IOM, HHS & CDC.
and more.......

Join Us

  Twitter  Facebook

 HCV Advocate Newsletter 

The HCV Advocate newsletter is a valuable resource designed to provide the hepatitis C community with monthly updates on events, clinical research, and education

November Newsletter

In This Issue

Game Changers:  AbbVie and Gilead 
Alan Franciscus, Editor-in-Chief

Lucinda K. Porter, RN

HEALTHWISE: Military Veterans and Hepatitis C) 
Lucinda K. Porter, RN

Prescription Drugs – Off-label Use
Alan Franciscus, Editor-in-Chief

Lucinda K. Porter, RN

 HCV Advocate
News & Pipeline Blog
Click Here

Hepatitis B
HBV Journal Review
HBV Journal Review November 2013

Connect With HCV Advocate

Twitter Facebook


News Updates

 Canadian Liver Foundation’s Newsroom
Liver in the News


Livewell is our e-newsletter exclusively for friends and donors of the Canadian Liver Foundation. Each issue highlights liver health issues, exciting research projects, upcoming events and includes profiles of our outstanding volunteers and donors.

The Livewell newsletter is distributed 4x per year. Please click here to fill in the form and we will be happy to add you to our subscriber list!

CLF updates you and interacts with you on all things liver
Stay Updated

Twitter   Facebook

Visit HepatitisCNews.com, an online community for those living with hepatitis C
Hep C TV - November 2013

Published on Nov 22, 2013
A monthly round-up of all things hep C! Taking a look at recent developments in hep C treatments, a tribute to the legendary musician Lou Reed and the latest contributions from our community here at Hepatitis C News.
November Spotlight On Series
Spotlight On ..... Naomi Judd
This week, in the second of our ‘Spotlight on…’ series, we profile American country singer Naomi Judd and her incredible work in the fight against hep C.
In this, the first in a regular series, we profile actress and model Pamela Anderson and her experience of living with the hep C virus.

****Watch "Hepatitis C News" YouTube Channel for a November Re-cap

Stay connected

 Twitter Facebook



The hepc.bull, has been “Canada’s hepatitis C journal” since the late 1990′s and has been published nonstop since 2001. The monthly newsletter contains the latest research results, government policy changes, activities and campaigns you can get involved in, articles by patients and caregivers, and a list of support groups plus other useful links.


HCV in the News

 Lou Reed

Andrew Cumming: My Story

And More!

Stay Connected

Twitter Facebook

CAP News
November News

CAP Hepatitis C Literature Review
Monthly Pubmed Review of the most relevant research on HCV

October Literature Review

Hepatitis C Choices
5th edition Free Online Book

Stay Connected With CAP


This Months Newsletters Not Yet Published - Check Back


 GI & Hepatology News is the official newspaper of the AGA Institute and provides the gastroenterologist with timely and relevant news and commentary about clinical developments and about the impact of health-care policy. The newspaper is led by an internationally renowned board of editors.
Today we have a newsletter update, GI & Hepatology News the official newspaper of the AGA Institute just published their montly newsletter.

Download the November Newsletter in either PDF or view the Interactive Version

In this issue

Sofosbuvir combo effective in unresponsive HCV
Coffee affects risk of liver vs. pancreatic cancer differently
Medicare may be covering HCV screening


Readers may have noticed a promo in the GI newsletter for "HCV HUB." Check out the news section of the HUB here, videos here, and homepage here.

Headlines At The HUB

Study identifies preferred approach to managing anemia from HCV treatment

Twitter  Facebook

NIH Website

****Check back for November Newsletter

Most Viewed

 Hot Topics

Sofosbuvir and Simeprevir

Recently, the FDA Antiviral Drugs Advisory Committee reviewed  Gilead's Sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and Johnson & Johnson's Simeprevir a protease inhibitor for the treatment of hepatitis C. 

The committee recommend the approval of simeprevir, in combination with pegylated interferon and ribavirin for the treatment of adult genotype 1 patients with compensated liver disease, including cirrhosis.

As for sofosbuvir, the panel voted unanimously in support of approving the drug in combination with just ribavirin for treating adult HCV genotypes 2/3 and in combination with pegylated interferon/ribavirin for genotype 1 and 4 treatment-naive patients. For detailed information please download the FDA review package for sofosbuvir and simeprevir.

The FDA does not have to follow the advice of its panels, but most often will. The U.S. health regulators are scheduled to decide whether to approve sofosbuvir by December 8, and simeprevir by November 27.

*Of Interest - sofosbuvir
First Interferon-Free HCV Regimen Gets Unanimously Positive Vote

Sofosbuvir-ledipasvir alone or with ribavirin

In the November issue of "The Lancet" researchers suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV including those with compensated cirrhosis or who have previously failed treatment with protease inhibitors. 

Commentary on the study by Paul E. Sax, MD, the Editor-in-Chief of  NEJM Journal Watch HIV/Aids Clinical Care;
by Paul E. Sax, MD
Imagine for a moment the ideal medical future … there’s a vaccine that prevents the common cold … colon cancer screening no longer requires that horrendous “prep” … electronic medical records are easily accessible, intuitive, secure, and all communicate effortlessly with one another … your doctor’s office has an actual person who answers the phone instead of a prerecorded list of “menu options” … and hepatitis C is cured with one pill a day taken for 8 weeks.

Not sure about the timeline for the first four, but based on this study of sofosbuvir and ledipasvir just published in the Lancet, the hepatitis C outcome is right around the corner:

In cohort A, SVR12 [no detectable virus 12 weeks after stopping treatment] was achieved by 19 (95%) of 20 patients (95% CI 75–100) in group 1, by 21 (100%) of 21 patients (84–100) in group 2, and by 18 (95%) of 19 patients (74–100) in group 3. In cohort B, SVR12 was achieved by 18 (95%) of 19 patients (74–100) in group 4 and by all 21 (100%) of 21 patients (84–100) in group 5 … These findings suggest that the fixed-dose combination of sofosbuvir-ledipasvir alone or with ribavirin has the potential to cure most patients with genotype-1 HCV, irrespective of treatment history or the presence of compensated cirrhosis. 

You’ll note that the “groups” were pretty small, and that only one of them — group 1 — actually got just the one-pill sofosbuvir/ledipasvir combination for 8 weeks, but regardless, these are pretty spectacular results. 

Even the most “complex” treatment group in this study received sofosbuvir/ledipasvir plus ribavirin for only 12 weeks, which is light years from the complexity of our current interferon-based therapies. Light years better, of course.

And since sofosbuvir has already been reviewed by the FDA advisory panel, we should be getting at least this drug by December 2013 at the latest; the combination pill with ledipasvir could be available some time next year (according to this article in the New York Times), and several other investigational HCV drugs will likely be approved soon as well (simeprevir this year too). But calm down already.

Take a deep breath. It’s a small phase II study. Shouldn’t we be more cautious? Shouldn’t we avoid wildly overstating the importance of this particular treatment approach? Of course, that’s the prudent thing to do.

But can people with HCV and their treaters be ecstatic about these results anyway? You betcha.

How Much? A Battle Over The Cost Of The New Hepatitis C Drugs
According to an article over at Pharmalot, Wall Street has estimated the cost of sofosbuvir to reach $80,000 to $90,000 per patient in the US. The high cost will put these drugs out of reach for low and middle-income countries. Columnist Ed Silverman mentioned a presentation at this months liver meeting which suggests a much lower cost then predicted by investment analysts. Andrew Hill of Liverpool University and colleagues presented a new analysis of predicted minimum costs to produce four next generation HCV DAAs, currently in Phase 3 development. The poster was also presented earlier this year at the 7th IAS Conference. Here is a quick rundown of predicted costs: $20-63 for a 12-week treatment of ribavirin, $10-30 for daclatasvir, $68-136 for sofosbuvir, $100-210 for faldaprevir and $130-270 for simeprevir (view the full analysis here)

Just In - Nov 13

Costs for Hepatitis C Treatment Skyrocket

Miriam E. Tucker
November 13, 2013

WASHINGTON, DC — The expense of telaprevir-based triple therapy for hepatitis C — including adverse event management — is $189,000 per sustained viral response, report investigators.

"Our findings indicate that the benefit-cost ratio is lower than projected, based on results of the registration trials," lead investigator Andrea Branch, MD, from the Icahn School of Medicine at Mount Sinai in New York City.
New data were presented at the meeting for both direct-acting antivirals and for some investigational agents used in combination regimens for patients with genotypes 1 to 4 hepatitis C. Several trials suggest the potential for interferon- and ribavirin-free all-oral regimens for genotypes 2 and 3 hepatitis C, and there is a variety of new combinations for the hard-to-treat genotype 1.

The New Paradigm of Hepatitis C Therapy - Integration of Oral Therapies Into Best Practices
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter in duration and simpler to administer.

Liver Deaths Cut Once HCV Viral Load Suppressed
Patients who achieved an undetectable viral load of hepatitis C virus (HCV) had decreased hepatic morbidity and mortality long-term, researchers found.

Hepatitis C, stigma and cure
Recently, an article titled "Hepatitis C, stigma and cure" published in the October issue of World J Gastroenterol, looked at the social stigma attached to HCV, consequences of living with the chronic infection, and new drugs to treat the virus.



AASLD - Interferon-Free HCV Tx Benefits Mentally Ill  -
WASHINGTON -- Hepatitis C (HCV) patients with mental comorbidities, such as depression or bipolar disorder, can be successfully treated with an interferon-free drug regimen, a phase II trial showed. Note that this uncontrolled trial demonstrated similar rates of virologic response among patients with and without psychiatric comorbidities treated with sofosbuvir and ribavirin....

AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients
A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of genotype 2 hepatitis C patients treated for 12 weeks and 85% of genotype 3 patients treated for 24 weeks, researchers reported last week at the 64th AASLD Liver Meeting in Washington, DC. A related study found that adding ribavirin to this combination may be an option for harder-to-treat individuals.

AASLD-Gilead Announces New Sustained Viral Response Data for Sofosbuvir-Based Regimens in Genotype 3-Infected Hepatitis C Patients
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from two studies, the Phase 3 VALENCE study and the Phase 2 LONESTAR-2 study, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients infected with genotype 3 HCV. These data will be presented this week at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) taking place in Washington, D.C.

AASLD-Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based Regimen for the Treatment of Hepatitis C in Patients Co-Infected With HIV
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients co-infected with HIV. In the trial, 76 percent (n=87/114) of genotype 1 HCV treatment-naïve patients receiving 24 weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks after completing therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV infection. These data will be presented this week during the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington, D.C.

Sofosbuvir-Based Regimens Liver Transplant Patients 

AASLD-Gilead Announces Phase 2 Results for Sofosbuvir-Based Regimens in Hepatitis C Patients Before and After Liver Transplantation
Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from two Phase 2 studies evaluating an all-oral treatment regimen of the investigational once-daily nucleotide analogue sofosbuvir plus ribavirin (RBV) for both the prevention and treatment of recurrent chronic hepatitis C virus (HCV) infection among patients who undergo liver transplantation. The findings will be presented this week at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting 2013) in Washington, D.C.

First Study of its Kind Shows that All-oral Treatment Regimen Prevents Hepatitis C Recurrence in Liver Transplant Recipients
For the first time, researchers have been able to prevent the recurrence of hepatitis C virus (HCV) infection in a large proportion of patients (64 percent, n=25/39) who undergo liver transplantation for cirrhosis complicated by hepatocellular carcinoma (HCC). This success was achieved with an interferon-free treatment regimen containing the oral antivirals sofosbuvir, an investigational agent, and ribavirin.

Slides: Pretransplant Sofosbuvir and Ribavirin to Prevent Recurrence of HCV Infection After Liver Transplantation

Sofosbuvir and Ledipasvir

A two-drug, single-pill HCV regimen with/without ribavirin -- led to viral cures in 97% of patients
In the so-called LONESTAR study, Lawitz and colleagues are testing the single-pill combination of sofosbuvir, a nucleotide polymerase inhibitor, and ledipasvir, which blocks the nonstructural NS5A protein

AASLD - HCV combo sofosbuvir and ledipasvir plus ribavirin yields 100% response rate
The addition of ribavirin to a fixed-dose combination of sofosbuvir and ledipasvir, two potent direct-acting hepatitis C antiviral drugs, increased the response rate from 70% to 100% in previously-treated patients with chronic hepatitis C infection and fibrosis or cirrhosis.

Fixed-Dose HCV Combo OK With Ribavirin Substitute
WASHINGTON -- A fixed-dose combination of two investigational hepatitis C (HCV) drugs needs a boost in patients with advanced fibrosis or cirrhosis, a researcher said here.
But the boost doesn't have to be the old stand by for HCV therapy, ribavirin, according to Edward Gane, MD, of Auckland Clinical Studies in Auckland, New Zealand...

AASLD- Gilead's hepatitis C Sofosbuvir/ledipasvir plus ribavirin or GS-9669
Interferon-free regimens of sofosbuvir and ledipasvir plus either ribavirin or GS-9669 taken for 12 weeks produced sustained response in 100% of treatment-experienced people with genotype 1 chronic hepatitis C virus (HCV) with advanced liver fibrosis or cirrhosis.

COSMOS - Simeprevir and Sofosbuvir

AASLD - COSMOS study with Simeprevir and Sofosbuvir in cirrhotic and non-cirrhotic HCV genotype 1 patients
Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced data from the interferon-free COSMOS study demonstrating safety and efficacy of the investigational protease inhibitor simeprevir (TMC435) in combination with the investigational nucleotide inhibitor sofosbuvir (GS-7977), with and without ribavirin, in genotype 1 chronic hepatitis C adult patients with compensated liver disease was presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C. during the late-breaking oral session on Monday, November 4....

HCV Combo Promising in Difficult Patients
WASHINGTON -- The combination of two novel hepatitis C (HCV) drugs that are close to market yielded good efficacy in hard-to-treat patients, a researcher said.


Simeprevir SVR in Treatment-Naïve and Treatment-Experienced Geno 1 Chronic Hepatitis C Patients
Beerse, Belgium (Nov. 11, 2013) Janssen R&D Ireland (Janssen) today announced the presentation of new data for the new generation protease inhibitor simeprevir (TMC435) in the treatment of genotype 1 chronic hepatitis C (HCV) in treatment-naïve and treatment-experienced adult patients with compensated liver disease. In analyses of the Phase 3 QUEST-1 and QUEST-2 studies in treatment-naïve patients and the Phase 3 PROMISE study in prior relapse patients, the efficacy of simeprevir was observed in HCV patients considered difficult to treat, including patients with the IL28B TT genotype and METAVIR scores of F4.

Daclatasvir and Asunaprevir

Daclatasvir plus Asunaprevir HCV Regimen: No Interferon, No Ribavirin, No Problem
WASHINGTON -- Patients who failed to respond to standard treatment for hepatitis C virus (HCV) infection achieved greater than 80% sustained virologic response at 24 weeks with an all-oral regimen that eschewed both interferon and ribavirin, researchers reported here.

AASLD-Phase III all-oral hepatitis C regimen daclatasvir and asunaprevir
For the 24-week study, 222 patients were studied, and 85.6 percent of those patients had a sustained virologic response (SVR) by week 12. According to Kazuaki Chayama, MD, PhD, "Only around 75 percent of patients treated with peg-interferon /ribavirin/telaprevir had a SVR but that therapy was associated with severe side effects and high cost. New oral-only drug therapy is quite safe and the eradication rate is so high."

Bristol seeks Japan approval of all-oral hepatitis C treatment
Patients in the trial were given a combination of daclatasvir, from a promising new class of drugs called NS5A inhibitors, and the protease inhibitor asunaprevir for 24 weeks. Those who had no detectable levels of the virus in their blood 24 weeks after completing the therapy were deemed to be cured, a measure known as SVR24, for sustained virologic response.

MK-5172 with MK-874

AASLD-High cure rates seen with Merck oral hepatitis drugs -study
A combination of two oral hepatitis C treatments developed by Merck & Co led to high cure rates in previously untreated patients, indicating the company is a contender in the race to find new treatments for the liver destroying virus.

MK-5172 - Oral HCV Combos Promising
WASHINGTON -- All-oral combinations of two novel drugs for hepatitis C (HCV) demonstrated promising efficacy in a small clinical trial, a researcher said here.

Merck's 'breakthrough' hep C combo plays catch-up 
Now its combination of MK-5172, an NS3/4A protease inhibitor, and the NS5A treatment MK-8742 produced cure rates ranging from 96% to 100% among small groups of genotype 1a and 1b patients. A total of 58 evaluable patients were included in the readout with the combo provided both with and without ribavirin.

Slides - MK-8742, an HCV NS5A Inhibitor With a Broad Spectrum of HCV Genotypic Activity, Demonstrates Potent Antiviral Activity in Genotype-1 and -3 HCV-Infected Patients

Resistance Analysis [and activity] of Genotype-1 and -3 HCV-Infected Patients Receiving MK-8742, an HCV NS5A Inhibitor With Potent Antiviral Activity, in a Ph1b Monotherapy Study

High Efficacy and Safety of the All-Oral Combination Regimen, MK-5172 / MK-8742 ± RBV for 12 Weeks in HCV Genotype 1 Infected Patients: The C-WORTHY Study

ABT-450/r, and ABT-267

HCV RNA "Target Detected" After "Target Not Detected" During IFN-free Treatment: Time to Worry or Not?

AASLD-New Data from from AbbVie's Study, ABT-450 Containing Regimen
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA  a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that additional data from AbbVie's M13-393 study, referred to as PEARL-I, will be presented in an oral presentation at 5:15 p.m. ET today at The Liver Meeting, the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, D.C.

AbbVie’s two-drug, interferon-free combination cures genotype 1b hepatitis C infection in 95%
AbbVie is already testing ABT-450, an HCV protease inhibitor boosted by ritonavir, and ABT-267, an Ns5A inhibitor, in several phase III studies in combination with a third drug, the non-nucleoside polymerase inhibitor ABT-333. These trials will begin to report results by the end of 2013, and it is likely that AbbVie will submit a licensing application in early 2014 for this three-drug, interferon-free combination in order to achieve marketing approval in the second half of 2014.....

HCV Drug Combo Cures Most in Select Group 
WASHINGTON -- An investigational two-drug combination treatment for hepatitis C (HCV) -- using none of the standard medications -- led to cures in 90% or more of a selected group of patients, a researcher said here.

In the PEARL-1 study, Lawitz and colleagues studied ABT-450/r, an HCV NS3/4A protease inhibitor boosted with the protease inhibitor ritonavir (Norvir), and ABT-267, which blocks the viral nonstructural protein NS5A.

Slides - Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions

Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 With SVR24 After Treatment With ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients With Chronic HCV Genotype 1 Infection in the AVIATOR Study


Of Interest - Aug 27 2013
Vertex’s VX-135 partial hold signals heightened FDA scrutiny toward HCV drugs
The FDA seems to be very sensitive about any compounds causing hepatotoxicity (liver damage) in HCV, said one expert, a US-based investigator. There is now a lot of focus on cardiac and hepatotoxicity due to Bristol-Myers Squibb’s (NYSE:BMY) failed purine nuc, he said.

Slides-Nov 7
VX-135, A Once-daily Nucleotide HCV Polymerase Inhibitor, Was Well Tolerated And Demonstrated Potent Antiviral Activity When Given With Ribavirin In Treatment-naïve Patients With Genotype 1 HCV

Faldaprevir/Deleobuvir/ PPI-668

Ongoing phase 2 trial finds RVR from all-oral regimen for HCV patients
WASHINGTON — An investigational, all-oral combination of protease inhibitor faldaprevir, non-nucleoside NS5B inhibitor deleobuvir and NS5A inhibitor PPI-668 with and without ribavirin has consistently demonstrated rapid virologic response among the hepatitis C genotype 1a population, a speaker said here.


Blog News Updates

AASLD Website

AASLD Coverage

HCV Advocate - Commentary by Alan Franciscus @ Top News from AASLD 2013

Commentary/Abstracts/Videos @ Healio

Capsule Summaries, review by experts and slides @ Clinical Care Options CCO

Commentary/Abstracts with coverage by Liz Highleyman @ hivandhepatitis.com

Slides/Abstracts @ NATAP

CME/CE with commentary by Michael Smith @ MedPage Today

Photo Credit

No comments:

Post a Comment